Oncologists Use Novel Chemotherapies On-Label More than Off-Label

This article originally appeared here.
Share this content:
Novel Chemotherapies More Often Used On- Than Off-Label
Novel Chemotherapies More Often Used On- Than Off-Label

(HealthDay News) -- In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

To examine the prevalence of off-label use of 10 commonly prescribed patent-protected anticancer drugs, Rena M. Conti, Ph.D., of the University of Chicago, and colleagues analyzed prescribing data from a pharmacy software provider maintaining a population-based cohort database including 570 medical oncologists in 122 medical oncology practices.

The researchers found that 70 percent of chemotherapy use was on-label, and 30 percent was off-label. Fourteen percent of chemotherapy use conformed to an off-label indication supported by the National Comprehensive Care Network (NCCN) recommendations. Ten percent of off-label use occurred at a U.S. Food and Drug Administration-approved cancer site but for a stage of cancer or line of therapy that was not recommended by the NCCN. Spending on these chemotherapies amounted to $2 billion for off-label and NCCN supported uses and $2.5 billion for off-label and NCCN unsupported uses, compared with $7.3 billion for on-label uses.

"The overall proportion of off-label use that the authors identified is not high, especially when taking into account NCCN-approved indications, but the variation by drug and the associated costs are high," write the authors of an accompanying editorial. "The ultimate goal should not be zero off-label prescribing, but rather that the entire system be designed to maximize the likelihood of an optimal risk-benefit ratio for both individual patients and the system as a whole."

One author disclosed financial ties to Genentech; a second author is an economic expert for plaintiffs in suit against the manufacturer of rituximab.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs